1 – 50 of 317
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
-
Mark
International Prophylaxis Study Group (IPSG) haemophilia joint MRI scale version 2.0
(
- Contribution to journal › Letter
-
Mark
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
2024) In Haemophilia(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Real-world prophylactic usage of recombinant factor IX Fc in Sweden : A report from the Swedish National Registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
-
Mark
Haemophilia A and B - evaluation of the Swedish prophylactic regimen by magnetic resonance imaging
(
- Contribution to journal › Article
-
Mark
Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children : Systematic and targeted literature reviews
(
- Contribution to journal › Scientific review
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
Primary prophylaxis in children with severe haemophilia A and B-Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts
(
- Contribution to journal › Article
-
Mark
Methods for anti-factor VIII antibody levels in haemophilia A patients-validation of a multiplec immunoassay and comparability with assays measuring non-neutralising and neutralising antibodies (inhibitors)
(
- Contribution to journal › Article
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Dilemmas on emicizumab in children with haemophilia A : A survey of strategies from PedNet centres
(
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
- 2022
-
Mark
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B : Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
(
- Contribution to journal › Article
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Long-term joint outcomes in adolescents with moderate or severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Sixth Åland Island Conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Autologous cell therapy - A new concept to eradicate inhibitors in haemophilia
(
- Contribution to journal › Letter
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
Bone mineral density in haemophilia – a multicentre study evaluating the impact of different replacement regimens
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Platelet function testing : Current practice among clinical centres in Northern Europe
(
- Contribution to journal › Article
- 2021
-
Mark
Collagen remodelling and plasma ascorbic acid levels in patients suspected of inherited bleeding disorders harbouring germline variants in collagen‐related genes
(
- Contribution to journal › Article
-
Mark
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
(
- Contribution to journal › Article
-
Mark
Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation
(
- Contribution to journal › Article
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Identification of F8 rearrangements in carrier and non-carrier mothers of haemophilia A patients
(
- Contribution to journal › Letter
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
-
Mark
Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors : A systematic literature review
(
- Contribution to journal › Scientific review
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
(
- Contribution to journal › Article
-
Mark
In response to WFH guidelines for the management of haemophilia, 3rd edition : Is there a difference between extended-half-life FVIII products or not?
(
- Contribution to journal › Letter
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
-
Mark
Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Achieving the unimaginable : Health equity in haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Genetic screening of children with suspected inherited bleeding disorders
(
- Contribution to journal › Article
-
Mark
Registries and databases : A European perspective
(
- Contribution to journal › Article
-
Mark
Critical appraisal of the International Prophylaxis Study Group magnetic resonance image scale for evaluating haemophilic arthropathy
(
- Contribution to journal › Article
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
(
- Contribution to journal › Article
-
Mark
WFH Guidelines for the Management of Hemophilia, 3rd edition
(
- Contribution to journal › Article
- 2019
-
Mark
Cardiovascular disease-related hospitalization and mortality among persons with von Willebrand disease : A nationwide register study in Sweden
(
- Contribution to journal › Article